Antifungal Activity of Colistin against *Mucorales* Species *In Vitro* and in a Murine Model of *Rhizopus oryzae* Pulmonary Infection

Ronen Ben-Ami, Russell E. Lewis, Jeffrey Tarrand, Konstantinos Leventakos, and Dimitrios P. Kontoyiannis

Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; College of Pharmacy, University of Houston, Houston, Texas; and Department of Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Received 10 July 2009/Returned for modification 23 August 2009/Accepted 17 October 2009

In immunosuppressed hosts, mucormycosis is a life-threatening infection with few treatment options. We studied the activity of colistin (polymyxin E) against *Mucorales* species *in vitro* and in a murine model of pulmonary *Rhizopus oryzae* infection. Colistin exhibited fungicidal activity *in vitro* against *Mucorales* spores and mycelia. At the colistin MIC, initial *R. oryzae* hyphal damage was followed by rapid regrowth; however, regrowth was prevented by combining colistin with a subinhibitory concentration of amphotericin B. Using electron microscopy and FM4-64 staining, we demonstrated that colistin disrupts *R. oryzae* cytoplasmic and vacuolar membranes, resulting in the leakage of intracellular contents. The prophylactic intranasal treatment of colistimethate significantly reduced the mortality rate and pulmonary fungal burden resulting from inhalational challenge with *R. oryzae* spores, whereas intraperitoneal colistimethate treatment had no effect. We conclude that colistin has modest *in vitro* and *in vivo* fungicidal activity against *Mucorales* spp. Further studies are warranted to assess the use of this drug in the prevention and treatment of mucormycosis.

During the past decade, pulmonary mucormycosis (PMM) has emerged as an important life-threatening opportunistic infection in severely immunocompromised patients, such as those with prolonged neutropenia and recipients of allogeneic hematopoietic stem cell transplantation (12, 21). In contrast to diabetic patients who develop rhinocerebral mucormycosis, surgical debridement is impractical in patients with PMM, and the correction of the underlying immunosuppression is challenging (12, 21); therefore, antifungal chemotherapy remains the chief therapeutic intervention for many patients with PMM. Unfortunately, *Mucorales* species are inherently resistant to most clinically available antifungal agents except amphotericin B, which is associated with renal and intestinal toxicity, and posaconazole, which is available only as an oral formulation and has variable absorption from the gastrointestinal tract (12, 21). Hence, there is an urgent need for novel drugs with activity against *Mucorales* spp.

Polymyxins are cyclic, positively charged peptide antibiotics produced by the bacterium *Bacillus polymyxa* (16). Polymyxins bind to and disrupt the anionic outer cell membrane of Gram-negative bacteria and have a neutralizing effect on bacterial lipopolysaccharides (16). Interestingly, polymyxin B also has been shown to disrupt the cytoplasmic and vacuolar membranes of the model yeast *Saccharomyces cerevisiae* (23), suggesting that its antimicrobial activity extends to eukaryotic organisms. We studied the activity of polymyxin E (colistin) against *Mucorales* spp. *in vitro* and in a murine model of PMM.

**MATERIALS AND METHODS**

**Isolates.** We performed susceptibility testing on 21 clinical *Mucorales* isolates recovered from patients at The University of Texas M. D. Anderson Cancer Center (Houston). Isolates were identified by standard morphological criteria, and the genus identification was confirmed by the sequencing of the ITS1-5.8S-ITS2 region of the fungal rRNA genes as described previously (13). The following isolates were tested: *Rhizopus* spp. (14 isolates), *Mucor* spp. (4 isolates), and *Cunninghamella* spp. (3 isolates). For comparison, four *Aspergillus fumigatus* and six *A. terreus* clinical isolates also were tested. *Rhizopus oryzae* 5799, a clinical strain that we previously used in a murine model of pulmonary infection (15), was selected for additional *in vitro* and animal studies, as detailed below. All isolates were grown on yeast extract agar glucose (YAG) plates for 48 to 72 h at 37°C. Spores were collected in sterile normal saline with 0.08% Tween 20, washed twice in normal saline, passed through 40-μm nylon filters (BD Biosciences, Franklin Lakes, NJ), and enumerated in a hemacytometer.

**Drugs.** For *in vitro* experiments, stock solutions of colistin sulfate (15 mg/ml; Sigma, St. Louis, MO) and amphotericin B (5 mg/ml; Sigma) were prepared in sterile water, separated into aliquots, and stored at −20°C until use. Colistimethate, the inactive prodrug of colistin sulfate, is a less toxic formulation used for parenteral treatment (16). Therefore, for *in vivo* studies, colistimethate (Xenogen Pharmaceuticals, Big Flats, NY) was reconstituted in sterile water at 30 mg/ml. Drugs were protected from light until use.

**Susceptibility testing.** Broth microdilution was performed as outlined by the Clinical and Laboratory Standards Institute (4). Serial colistin dilutions and drug-free controls were prepared in RPMI 1640 with glutamine and without bicarbonate (64 to 0.12 μg/ml) or in yeast nitrogen base (YNB) complete medium (128 to 0.12 μg/ml) and dispensed in microtiter plates (100 μl per well). Freshly collected spores were suspended in the test medium at 0.5 × 10⁶ to 4 × 10⁷ cells/ml, and 100 μl was inoculated into each drug-containing well and drug-free control wells. Plates were incubated at 37°C for 24 h, and the MIC was determined visually as the lowest drug concentration resulting in 100% growth inhibition. The colistin minimum fungicidal concentration (MFC) was determined as described previously (5). Briefly, 20-μl suspensions from each well that showed the complete inhibition of growth and from the last positive well (showing growth similar to that in the control well) were subcultured onto YAG plates. The MFC was defined at 24 h as the lowest drug concentration at which fewer than three colonies were observed, which corresponded to a killing activity of ≥99.9%.

To study the interaction between colistin and amphotericin B against *R. oryzae*, we performed checkerboard experiments with microtiter plates containing combinations of colistin (0.06 to 64 μg/ml) and amphotericin B (0.125 to 8 μg/ml), as...
previously described (3). The fractional inhibitory concentration index (FICI) was calculated for checkerboard plates; values were interpreted as follows: FICI ≤ 0.5, synergy; 0.5 ≤ FICI < 4, indifference; and FICI > 4, antagonism (3, 18).

Although the poor agar diffusion characteristics of colistin limit the accuracy of disk diffusion assays, this method still may provide useful susceptibility data (7). Disk diffusion assays were performed using sterile paper disks (Fisher Scientific, Rochester, NY) containing 8 to 32 μg of colistin and RPMI 1640 plates inoculated with 200 μl of spore suspension (10^6 cells/ml). Inhibition zones were measured after 24 h of incubation at 37°C.

DiBAC viability staining. To determine whether colistin exerts fungicidal activity against R. oryzae mycelia, we performed viability staining with bi-(1,3-dibutylbarbituric acid) trimethine oxonol (DiBAC) (Molecular Probes, Carlsbad, CA) on drug-exposed and unexposed mycelia, as previously described (2). R. oryzae spores were grown to mycelia in microtiter tubes with RPMI 1640 plus 0.15% (wt/vol) JunIon (Nihon Junyaku, Tokyo, Japan) at 37°C with shaking for 18 h. Tubes were centrifuged at 13,000 × g to remove the media, and mycelia were resuspended in RPMI containing colistin at the MIC or MFC; amphotericin B (2 μg/ml) and drug-free medium served as the positive and negative controls, respectively. Tubes were incubated for 6 h at 37°C with shaking. Mycelia next were washed twice in 3-(N-morpholino) propane sulfonic acid (MOPS) at pH 7 (designated MOPS7), and DiBAC was added from 1 mg/ml stock in 100% ethanol at 2 μg/ml in MOPS7. Tubes were incubated with gentle shaking (50 to 100 rpm) at ambient temperature in the dark for 1 h. Samples then were washed twice in MOPS7 and stored on ice until fluorescent microscopy. Images were acquired under a triple-band fluorescence microscope (Olympus BX-51; Olympus, Melville, NY) using the fluorescein isothiocyanate (FITC) filter.

Flow cytometry. The effect of colistin on germination was determined by XTT reduction assay. We determined the time course of colistin-induced hyphal damage with the use of the 2,3-bis[2-methoxy-4-nitro-5-(sulfonyl amino) carbonyl]-2H-tetrazolium-5-carboxanilide (XTT) colorimetric formazan reduction assay. R. oryzae mycelia were suspended in RPMI 1640 containing various concentrations of colistin, amphotericin B, or both and incubated in microtiter tubes at 37°C with shaking. Drug-free RPMI 1640 was used as the control medium. At the 0-, 2-, 6-, and 24-h time points, tubes were removed from incubation and centrifuged at 13,000 × g for 5 min. The medium was aspirated, and 1 ml of XTT (Sigma) plus 0.17 mg of menadione (Sigma) was added in 1 ml of phosphate-buffered saline (PBS) to each tube. Tubes were incubated at 37°C for an additional 1 h, and absorbance was measured at 405 nm. Hyphal viability for each time point and drug concentration was calculated as the optical density at 405 nm (OD405) of the drug-containing well divided by the OD405 of the control well. All experiments were performed at least three times.

The combined effects of colistin and amphotericin B were calculated as follows. For each experiment, the hyphal damage produced by each drug alone after 24 h of exposure was calculated and compared to the effect of treatment with the combination of both drugs. Synergism was defined as an antifungal effect of the combination treatment that was greater than the sum of the effects of each drug alone. Indifference was defined as an antifungal effect of the combination treatment that was greater than the effect produced by either drug alone but that did not reach synergism. Antagonism was defined as an antifungal effect of the combination which was less than the effect produced by either drug alone (24).

Post-antifungal effect. To determine the period of fungal growth inhibition after colistin exposure, we incubated R. oryzae spores (10^6/ml) in RPMI 1640 with colistin for 60 min, washed the spores three times in RPMI to remove the drug, and resuspended them in drug-free RPMI. The spore suspension was inoculated into 96-well plates (100 μl/well) and incubated at 37°C. The OD405 was measured every 10 min in a spectrophotometer (Power Wave HT, Biotek, Winooski, VT). Wells containing RPMI alone were used to correct for background absorbance. The lag time to the initiation of logarithmic growth was determined for each drug concentration, and the post-antifungal effect period was calculated as the lag time of the drug-containing well minus the lag time of the drug-free well.

ATP release assay. We next measured intracellular ATP efflux from colistin-exposed germlings as an indication of cell membrane damage and cytoplasmic leakage (11). R. oryzae spores were enumerated in a hemocytometer and suspended in RPMI 1640 at 10^6 cells/ml. Spore suspensions then were incubated at 37°C and observed periodically until most cells had germinated (~6 h). Germ- lings were separated from the medium by centrifugation and resuspended in 1-ml aliquots of RPMI 1640 containing colistin in the MIC or MFC and in drug-free RPMI at 37°C with shaking. The cells were removed by centrifugation after 5, 30, 60, and 90 min of incubation, and the supernatants were assayed for ATP using the CellTiter-Glo luminescent kit (Promega, Madison, WI). Data were collected with a microplate luminometer (Spectramax M5; Molecular Devices, Sunnyvale, CA).
treatment of research animals and were approved by the M. D. Anderson Cancer Center institutional animal care and use committee.

Mouse lungs were excised, and the fungal burden was measured using real-time quantitative PCR (RT-qPCR) for the R. oryzae rRNA gene, as previously described (15). In brief, DNA was extracted from lung homogenates using the DNeasy tissue kit (Qiagen, Valencia, CA), and DNA samples were amplified in duplicate using the ABI PRISM 7000 sequence detection system (Applied Biosystems, Foster City, CA). Primers and dual-labeled fluorescent hybridization probes specific for R. oryzae were designed using the ABI PRISM SeqScape software program (version 2; Applied Biosystems). The oligonucleotide sequences were the following: (i) sense amplification primer, 5′-AGGGCTTGGTCGACGACGC-3′; (ii) antisense amplification primer, 5′-TCCGTCGGCAGACTTGCAG-3′; and (iii) hybridization probe, 5′-6-carboxyfluorescein-TGCTACTGTTGCAGACCGCCGCT-6-carboxytetramethylrhodamine-3′. The threshold cycle (C\text{t}) of each sample was interpolated from a 6-point standard curve of spore equivalents of R. oryzae DNA.

Statistical analysis. Continuous variables with normal value distribution (hyphal viability and ATP concentration in supernatants) were compared between treatment and control groups using Student’s t test. Pulmonary fungal burdens, which had a nonnormal value distribution, were compared among the different animal groups using the nonparametric Kruskal-Wallis test, and Dunn’s test was used for post hoc comparisons between each treatment group and the control group. Calculations were performed using Instat (GraphPad, San Diego, CA). Survival curves were plotted using the Kaplan-Meier method. The survival curves of different treatment groups were compared using the log-rank test. Two-sided P values of <0.05 were considered statistically significant.

RESULTS

Colistin has antifungal activity in vitro against Mucorales spores and mycelia. Susceptibility testing by broth microdilution in RPMI 1640 generally revealed clear end points with complete growth inhibition. For Mucorales isolates, the median colistin MIC was 16 μg/ml (range, 8 to 32 μg/ml) (Table 1). Colistin was fungicidal at concentrations of one to four times the MIC (median MFC/MIC ratio, 2). In contrast, the colistin MICs for all Aspergillus isolates tested were ≥64 μg/ml (data not shown). Colistin MICs against all Mucorales isolates were higher (128 μg/ml) when YNB was used as the test medium (Table 1). Disk diffusion testing yielded clear zones of inhibition with a median diameter of 18 mm for 8-μg colistin disks, 19 mm for 16-μg colistin disks, and 21 mm for 32-μg colistin disks (Fig. 1).

DiBAC vital staining revealed enhanced uptake in colistin-exposed R. oryzae hyphae compared to that in non-colistin-exposed hyphae. Extensive DiBAC uptake, indicating fungicidal drug activity, was observed at a colistin concentration of 32 μg/ml; i.e., the MFC for the R. oryzae 5799 strain (Fig. 2).

Colistin MICs and MFCs for 21 clinical Mucorales isolates

<table>
<thead>
<tr>
<th>Isolate</th>
<th>RPMI 1640</th>
<th>YNB</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MIC</td>
<td>MFC</td>
</tr>
<tr>
<td>Cunninghamella bertholletiae 5633</td>
<td>16</td>
<td>64</td>
</tr>
<tr>
<td>Cunninghamella bertholletiae 6694</td>
<td>16</td>
<td>64</td>
</tr>
<tr>
<td>Cunninghamella bertholletiae 6733</td>
<td>32</td>
<td>64</td>
</tr>
<tr>
<td>Mucor circinelloides 4030</td>
<td>16</td>
<td>64</td>
</tr>
<tr>
<td>Mucor circinelloides 4480</td>
<td>16</td>
<td>32</td>
</tr>
<tr>
<td>Mucor circinelloides 4818</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>Mucor circinelloides 5904</td>
<td>16</td>
<td>64</td>
</tr>
<tr>
<td>Rhizopus oryzae 4549</td>
<td>32</td>
<td>64</td>
</tr>
<tr>
<td>Rhizopus oryzae 3140</td>
<td>16</td>
<td>32</td>
</tr>
<tr>
<td>Rhizopus oryzae 4153</td>
<td>16</td>
<td>64</td>
</tr>
<tr>
<td>Rhizopus sp. 4523</td>
<td>16</td>
<td>64</td>
</tr>
<tr>
<td>Rhizopus oryzae 5879</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>Rhizopus homothallicus 5790</td>
<td>16</td>
<td>64</td>
</tr>
<tr>
<td>Rhizopus homothallicus 5910</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>Rhizopus oryzae 5799</td>
<td>8</td>
<td>32</td>
</tr>
<tr>
<td>Rhizopus oryzae 5496</td>
<td>16</td>
<td>32</td>
</tr>
<tr>
<td>Rhizopus microsporus 6164</td>
<td>32</td>
<td>64</td>
</tr>
<tr>
<td>Rhizopus oryzae 6093</td>
<td>16</td>
<td>32</td>
</tr>
<tr>
<td>Rhizopus oryzae 6725</td>
<td>16</td>
<td>32</td>
</tr>
<tr>
<td>Rhizopus homothallicus 6360</td>
<td>32</td>
<td>64</td>
</tr>
<tr>
<td>Rhizopus bertholletiae 6254</td>
<td>16</td>
<td>32</td>
</tr>
</tbody>
</table>

* MICs and MFCs are in micrograms/milliliter.

FIG. 1. Colistin disk diffusion assay. Paper disks containing 8, 16, and 32 μg of colistin (Col) were placed on yeast extract agar glucose plates inoculated with a 10⁶/ml R. oryzae spore suspension. Clear inhibition zones, measured 24 h later, revealed a colistin dose-response relationship.
posed *R. oryzae* germlings using transmission electron microscopy. Compared to those of non-drug-exposed germlings, a marked increase in the number and size of vacuoles was seen in colistin-treated germlings (Fig. 5). Moreover, the vacuoles of colistin-treated germlings appeared ruffled and dysmorphic. These changes were most severe in germlings exposed to colistin at the MFC, in which much of the cytoplasm was occupied by swollen vacuoles (Fig. 5). In addition, we observed bleb formation adjacent to the cell membrane, suggesting cell membrane disruption in colistin-exposed *R. oryzae* germlings. To confirm these observations, we performed fluorescent microscopy with FM4-64, which stains cellular and vacuolar membranes (25). In non-colistin-exposed germlings, FM4-64 was concentrated in the plasma membrane and germ tube tips, reflecting the known aggregation of secretory vesicles in *Mucorales* hyphal tips (9). In contrast, in colistin-exposed germlings, FM4-64 was redistributed to vacuoles throughout the cytoplasm, whereas the cell membrane and hyphal tips were not enhanced by the dye (Fig. 5). At the highest colistin concentrations, vesicles appeared swollen and malformed, and FM4-64 was dispersed in the cytoplasm, indicating vacuolar damage and disruption (Fig. 5).

**Intranasal colistimethate protects mice from pulmonary *R. oryzae* infection.** To determine whether the observed *in vitro* activity of colistin translates into meaningful activity in an...
animal mucormycosis model, we studied two colistimethate regimens in immunosuppressed mice. Treatment with i.p. colistimethate did not significantly affect the mortality rate of BALB/c mice infected intranasally with *R. oryzae* spores (Fig. 6A). In contrast, the prophylactic intranasal administration of colistimethate increased the survival rate at 10 days from 33 to 61% (*P* = 0.002 by the log-rank test) (Fig. 6A). Moreover, the pulmonary fungal burden of mice treated prophylactically with intranasal colistimethate was significantly lower than that of untreated mice (*P* < 0.001) and was below the assay’s lower detection limit in 84% of mice in this treatment group. The fungal burden was increased in the lungs of mice treated with i.p. colistimethate relative to that of the control group (*P* < 0.01) (Fig. 6B).

**DISCUSSION**

We found that colistin has fungicidal *in vitro* activity against *Mucorales* spores and mycelia. The antifungal effect of colistin apparently was mediated by its disruptive activity on *Mucorales* cytoplasmic and vacuolar membranes. Moreover, the intranasal administration of colistimethate significantly reduced the mortality rate of immunosuppressed BALB/c mice challenged with *R. oryzae* spores. Taken together, these observations suggest that colistin has clinical applications in the prevention and treatment of mucormycosis in immunosuppressed hosts.

*Mucorales* isolates had colistin MICs of 8 to 32 μg/ml (MIC<sub>50</sub>, 16 μg/ml) in RPMI 1640; MFCs were one to four times the MICs (median MFC/MIC, 2). In human studies, single doses of 75 to 150 mg colistin base produced serum concentrations of bioactive colistin of 6 to 18 μg/ml (8, 20); higher colistin concentrations (13 to 32 μg/ml) were measured during The prolonged therapy of patients with cystic fibrosis (22). Thus, fungicidal concentrations of colistin may be difficult to achieve with intravenous dosing but may be attained locally in the lungs using aerosolized drug delivery.

Colistin MICs against *Mucorales* were affected by the test medium; MICs were significantly higher in YNB complete medium than those in RPMI 1640. The *in vitro* activity of colistin against Gram-negative bacteria is known to be affected by the concentrations of divalent cations, which compete for binding sites on the bacterial outer membrane (10). YNB contains higher concentrations of calcium and magnesium (0.9 and 4.1 mM, respectively) than those of RPMI 1640 (0.42 and 0.40 mM, respectively), which could explain the attenuated activity of colistin in YNB.

We found no post-antifungal effect of colistin against *R. oryzae*. Furthermore, XTT reduction assays revealed that the...
initial damage caused to \textit{R. oryzae} hyphae as a result of exposure to colistin at the MIC was followed rapidly by fungal regrowth. This phenomenon was negated by the addition of a subinhibitory concentration of amphotericin B, which is consistent with the synergistic activity of these two drugs against \textit{R. oryzae}. Interestingly, similar observations regarding the antibacterial activity of colistin (14, 19) have led researchers to suggest that colistin should be combined with other antimicrobial agents (14). Intranasal colistimethate prophylaxis in immunosuppressed mice reduced but did not completely prevent mortality from pulmonary mucormycosis, suggesting that this drug has modest antifungal activity \textit{in vivo}. Therefore, colistin should be explored as an adjunct treatment for mucormycosis.

Colistin had no effect on mortality rates when administered i.p. after the intranasal inoculation of \textit{R. oryzae} spores. This finding likely reflects the rapid clearance of systemically administered colistimethate observed in our pharmacokinetic experiment. The half-life of colistimethate in the lung after intranasal administration previously was shown to be significantly longer than that of systemically dosed colistimethate (50 versus 11 min) (1), which may explain the relative efficacy of the intranasal route in our animal model. In addition, the earlier (prophylactic) administration of intranasal colistimethate may have accounted for its efficacy.

The clinical use of colistin has increased in recent years because of its activity against multidrug-resistant Gram-negative bacteria (16). Newly manufactured colistin formulations are associated with lower rates of nephrotoxicity than historically reported rates (16), expanding the application of this drug to a wider range of critically ill patients. Colistin has been aerosolized for inhalational use in the treatment and prevention of pneumonia caused by Gram-negative bacteria (6). This mode of colistin administration may be particularly appealing for the adjunct treatment of sinopulmonary mucormycosis, because high drug concentrations are achieved in the airways with minimal systemic toxicity.

Unexpectedly, colistin had no \textit{in vitro} activity against \textit{Aspergillus} isolates. This selective activity suggests that the disruption of fungal membranes by colistin depends on the presence of specific receptors. Similarly, the activity of colistin against Gram-negative bacteria is facilitated by binding to the lipid A moiety of lipopolysaccharide; variations in lipid A structure render certain Gram-negative bacteria, such as \textit{Pseudomonas mirabilis} and \textit{Burkholderia cepacia}, intrinsically resistant to colistin (16).

In conclusion, given the currently limited treatment options for mucormycosis in immunosuppressed patients, our findings should prompt further preclinical and clinical studies to evaluate the use of colistin for the treatment and prevention of this life-threatening infection.

\section*{ACKNOWLEDGMENTS}

We thank Kenneth Dunner, Jr., for his expert help with our electron microscopy studies.

This work was supported by Institutional Core Grant CA16672 from the High-Resolution Electron Microscopy Facility, M. D. Anderson Cancer Center.

\begin{thebibliography}{99}
\bibitem{4} Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. \textit{Ap-

\FIGURE{6} In \textit{vivo} activity of colistin in a murine model of pulmonary mucormycosis. The \textit{in vivo} activity of colistin was studied in BALB/c mice immunosuppressed with cyclophosphamide and cortisone acetate and inoculated intranasally with \textit{R. oryzae} spores. Treatment with intraperitoneal colistimethate (80 mg/kg/day) had no effect on the mortality rate in this model (A), whereas prophylaxis with intranasal colistimethate (5 mg/kg/day) significantly reduced the mortality rate ($P = 0.002$ by the log-rank test) (A) and pulmonary fungal burden, as determined by RT-qPCR ($P < 0.001$) (B). The pulmonary fungal burden was increased in mice treated with colistin i.p. relative to that of untreated control mice ($P < 0.01$).

\section*{REFERENCES}

proven standard, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.


Downloaded from http://aac.asm.org/ on June 24, 2017 by guest